SMS Pharmaceuticals Q3 FY25: Revenue ₹173.35 Cr, PAT ₹18.24 Cr
Q3 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹173Cr
- +7.5% YoY
- −12.2% QoQ
- Net profit
- ₹18Cr
- +63.6% YoY
- +28.6% QoQ
- Margin
- 19%
- +1 pp YoY
- +3 pp QoQ
Guidance rank: #51 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on SMS Pharmaceuticals Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). EBITDA for Q3FY25: ₹33.21 crore, up 15% YoY (Page 18 & 5) - EBITDA Margin for Q3FY25: 19%, up 120 bps YoY (Page 18 & 5) - Profit After Tax (PAT) for Q3FY25: ₹18.24 crore, up 59% YoY (Page 18 & 5) - PAT Margin for Q3FY25: 11%, up 341 bps YoY (Page 18) - Operating margin/outlook: The presentation notes margin expansion aided by backward integration and favorable product mix (Page 18).
From SMS Pharmaceuticals Ltd's Q3 FY25 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5).
- Volume growth cited as a driver for revenue increase across the product portfolio (Page 18).
- 9MFY25 revenue at ₹534.55 crore, up 15% YoY from ₹463.47 crore in 9MFY24 (Page 18).
- EBITDA grew 15% YoY with margin expansion; PAT increased 59% YoY (Page 4, 5).
- Outlook states "Robust growth is expected in revenue and profitability" driven by portfolio approach and cost optimization (Page 17).
2 more points from SMS Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what SMS Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ongoing capex of ₹150 crore focused on backward integration and capacity expansion (Page 16).
- Aim to achieve a production target of 1,000 MT per month for ibuprofen to achieve global scale (Page 16).
- 2nd phase of backward integration project is complete; trial runs ongoing with commercial production set for March 2025 (Page 4).
- Capacity expansion project remains on track for completion by FY26 (Page 4).
2 more points from SMS Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what SMS Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
SMS Pharmaceuticals Ltd — Quarterly revenue & net profit
SMS Pharmaceuticals Ltd Q3 FY25 results — key figures
| ₹ Cr | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 173 | 161 | +7.5% | 197 | -12.2% |
| Operating profit (EBITDA) | 33 | 29 | +13.8% | 31 | +6.5% |
| Operating margin | 19% | 18% | +1 pp | 16% | +3 pp |
| Profit before tax | 22 | 17 | +29.4% | 20 | +10% |
| Net profit (PAT) | 18 | 11 | +63.6% | 14 | +28.6% |
| EPS (₹) | 2.15 | 1.36 | +58.1% | 1.66 | +29.5% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹316 Cr, net profit ₹40 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What SMS Pharmaceuticals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Wockhardt (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- NGL Fine Chem (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
- Themis Medicare (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
SMS Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were SMS Pharmaceuticals Ltd Q3 FY25 results?
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). EBITDA for Q3FY25: ₹33.21 crore, up 15% YoY (Page 18 & 5) - EBITDA Margin for Q3FY25: 19%, up 120 bps YoY (Page 18 & 5) - Profit After Tax (PAT) for Q3FY25: ₹18.24 crore, up 59% YoY (Page 18 & 5) - PAT Margin for Q3FY25: 11%, up 341 bps YoY (Page 18) - Operating margin/outlook: The presentation notes margin expansion aided by backward integration and favorable product mix (Page 18).
What is SMS Pharmaceuticals Ltd share price analysis?
SMS Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 40.5 with a market cap of ₹4,148 Cr. Investors should review the full earnings analysis for detailed insights.
Is SMS Pharmaceuticals Ltd planning capital expenditure?
Ongoing capex of ₹150 crore focused on backward integration and capacity expansion (Page 16).
Keep SMS Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
